InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing

InMed Pharmaceuticals Inc.

2025-Q3 EPS reported -$7.93 revenue$3,637,923

Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.
BayMedica revenue $1.26M (+8% YoY); gross margin declined due to pricing pressure.
Cash and equivalents $4.68M (Jun 30, 2024: $6.57M); expects to fund operations into Q3 2025.
R&D expenses $0.91M vs $0.65M YoY, driven by INM-901 and INM-089 programs.
Company seeks additional financing through equity, debt, or collaborations to fund pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.